B Astruc

Modulation of Blood Pressure by Central Melanocortinergic Pathways

Jerry R. Greenfield, Jeffrey W. Miller, Julia M. Keogh et al. · New England Journal of Medicine · 2008 · 470 citations · Full text

Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles

B Astruc, Peter Marbach, Hakim Bouterfa et al. · The Journal of Clinical Pharmacology · 2005 · 121 citations

Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects

François Giuliano, Steven A. Kaplan, Marie‐Josée Cabanis et al. · Urology · 2006 · 56 citations

Thrombosis, Hypertension, Phosphodiesterase-5 Inhibitor Tadalafil +12

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

Daniela Baldoni, Shirin Bruderer, Andreas Krause et al. · Clinical Drug Investigation · 2014 · 40 citations

First-in-man Trial, Pharmacology, New Reversible +4

Effect of brivaracetam on cardiac repolarisation – a thorough QT study

Dominique Rosillon, B Astruc, R. Hulhoven et al. · Current Medical Research and Opinion · 2008 · 35 citations